+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Does a Positive Axillary Lymph Node Needle Biopsy Result Predict the Need for an Axillary Lymph Node Dissection in Clinically Node-Negative Breast Cancer Patients in the ACOSOG Z0011 Era?



Does a Positive Axillary Lymph Node Needle Biopsy Result Predict the Need for an Axillary Lymph Node Dissection in Clinically Node-Negative Breast Cancer Patients in the ACOSOG Z0011 Era?



Annals of Surgical Oncology 23(4): 1123-1128



American College of Surgeons Oncology Group (ACOSOG) Z0011 defined clinical node negativity by physical examination alone. Although axillary ultrasound with biopsy has a positive predictive value for lymph node (LN) metastases approaching 100 %, it may not appropriately identify clinically node-negative women with ≥3 positive LNs who require axillary lymph node dissection (ALND). We sought to identify the total number of positive LNs in women presenting with cT1-2N0 breast carcinoma with a positive preoperative LN biopsy to evaluate the potential for overtreatment when ALND is performed on the basis of a positive needle biopsy in patients who otherwise meet ACOSOG Z0011 eligibility criteria. Patients with cT1-2N0 breast cancer by physical examination with a positive preoperative LN biopsy were identified from a prospective institutional database. Clinicopathologic characteristics and axillary imaging results were compared between women with 1 to 2 total positive LNs and ≥3 total positive LNs. Between May 2006 and December 2013, a total of 141 women with cT1-2N0 breast cancer had abnormal axillary imaging and a preoperative positive LN biopsy (median patient age 51 years, median tumor size 2.4 cm, 86 % ductal histology, 79 % estrogen receptor positive). Sixty-six women (47 %) had 1 to 2 total positive LNs, and 75 (53 %) had ≥3 total positive LNs. Women with ≥3 total positive LNs had larger tumors (2.4 vs. 2.2 cm, p = 0.03), fewer tumors with ductal histology (79 vs. 94 %, p = 0.01), more lymphovascular invasion (80 vs. 61 %, p = 0.01), and higher median body mass index (29.2 vs. 27.1 kg/m(2), p = 0.04). Having >1 abnormal LN on axillary imaging was significantly associated with having ≥3 total positive LNs at final pathology (68 vs. 43 %, p = 0.003). Axillary imaging with preoperative LN biopsy does not accurately discriminate low- versus high-volume nodal disease in clinically node-negative patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057651412

Download citation: RISBibTeXText

PMID: 26553439

DOI: 10.1245/s10434-015-4944-y


Related references

Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: retrospective comparative evaluation of clinically axillary lymph node positive and negative patients, including those with axillary lymph node metastases confirmed by fine needle aspiration. Bmc Cancer 16(1): 808, 2016

Should ACOSOG Z0011 change practice with respect to axillary lymph node dissection for a positive sentinel lymph node biopsy in breast cancer?. Clinical and Experimental Metastasis 29(7): 687-692, 2012

Higher axillary lymph node metastasis burden in breast cancer patients with positive preoperative node biopsy: may not be appropriate to receive sentinel lymph node biopsy in the post-ACOSOG Z0011 trial era. World Journal of Surgical Oncology 17(1): 37, 2019

Which sentinel lymph-node (SLN) positive breast cancer patient needs an axillary lymph-node dissection (ALND)--ACOSOG Z0011 results and beyond. Breast 22(3): 211-216, 2013

Which sentinel lymph-node SLN positive breast cancer patient needs an axillary lymph-node dissection ALND – ACOSOG Z0011 results and beyond. The Breast 22(3): 211-216, 2013

The Exportability of the ACOSOG Z0011 Criteria for Omitting Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy Findings: A Multicenter Study. Breast Diseases: A Year Book Quarterly 25(1): 60-61, 2014

The exportability of the ACOSOG Z0011 criteria for omitting axillary lymph node dissection after positive sentinel lymph node biopsy findings: a multicenter study. Annals of Surgical Oncology 20(8): 2556-2561, 2013

Should ACOSOG Z11 change practice with respect to axillary lymph node dissection for a positive sentinel lymph node biopsy in breast cancer?. Clinical & Experimental Metastasis 29(7): 687-692, 2012

Axillary Irradiation as an Imperative Alternative to Axillary Dissection in Clinically Lymph Node-Negative but Sentinel Node-Positive Breast Cancer Patients?. Breast Care 6(5): 353-358, 2011

Sentinel lymph node biopsy after neoadjuvant chemotherapy predicts pathological axillary lymph node status in breast cancer patients with clinically positive axillary lymph nodes at presentation. International Journal of Clinical Oncology 18(3): 547-553, 2013

Partial axillary lymph node dissection inferior to the intercostobrachial nerves complements sentinel node biopsy in patients with clinically node-negative breast cancer. Bmc Surgery 15: 79, 2015

What is the optimal method to predict axillary lymph node metastases in breast cancer patients?: Is sentinel lymph node biopsy ready to be an alternative to complete axillary dissection?. Japanese Journal of Clinical Oncology 29(12): 595, 1999

What is the optimal method to predict axillary lymph node metastases in breast cancer patients? Is sentinel lymph node biopsy ready to be an alternative to complete axillary dissection?. Japanese Journal of Clinical Oncology 29(12): 595, 1999

Trade-offs associated with axillary lymph node dissection with breast irradiation versus breast irradiation alone in patients with a positive sentinel node in relation to the risk of non-sentinel node involvement: implications of ACOSOG Z0011. Breast Cancer Research and Treatment 138(1): 205-213, 2013

Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients. European Journal of Surgical Oncology 35(8): 805-813, 2009